<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03889366</url>
  </required_header>
  <id_info>
    <org_study_id>NXP001_01</org_study_id>
    <nct_id>NCT03889366</nct_id>
  </id_info>
  <brief_title>Relative Bioavailability of NXP001 Compared to Emend® in Healthy Volunteers</brief_title>
  <official_title>Relative Bioavailability of NXP001 Compared to Emend® in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nuformix Technologies Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nuformix Technologies Limited</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will compare the relative bioavailability of both an oral capsule formulation and
      an oral suspension formulation of NXP001 to Emend® in healthy male volunteers in the fasted
      state.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 20, 2019</start_date>
  <completion_date type="Actual">April 30, 2019</completion_date>
  <primary_completion_date type="Actual">April 15, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area Under the Curve (AUC(0 to Infinity)) Following Single Dose Administration of NXP001 oral capsule, NXP001 oral suspension or Emend® in the fasted state</measure>
    <time_frame>through 48 hours postdose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Peak Plasma Concentration (Cmax) Following Single Dose Administration of NXP001 oral capsule, NXP001 oral suspension or Emend® in the fasted state</measure>
    <time_frame>through 48 hours postdose</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>NXP001 Oral Capsule</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>NXP001 Oral Suspension</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Emend®</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aprepitant 125 mg</intervention_name>
    <description>Single dose in the fasted state during treatment period 1,2 or 3</description>
    <arm_group_label>Emend®</arm_group_label>
    <arm_group_label>NXP001 Oral Capsule</arm_group_label>
    <arm_group_label>NXP001 Oral Suspension</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Healthy males

          2. Body mass index (BMI) of 18.0 to 35.0 kg/m2 as assessed at screening

          3. Must be willing and able to communicate and participate in the whole study

          4. Must provide written informed consent

          5. Must agree to use adhere to the contraception requirements of the study

        Exclusion Criteria:

          1. Subjects who have received any IMP in a clinical research study within the previous 3
             months prior to first dose

          2. Subjects who are study site employees, or immediate family members of a study site or
             sponsor employee

          3. History of any drug or alcohol abuse in the past 2 years

          4. Regular alcohol consumption &gt;21 units per week (1 unit = ½ pint beer, 25 mL of 40%
             spirit, 1.5 to 2 Units = 125 mL glass of wine, depending on type)

          5. Current smokers and those who have smoked within the last 12 months. A breath carbon
             monoxide reading of greater than 10 ppm at screening

          6. Current users of e-cigarettes and nicotine replacement products and those who have
             smoked these products within the last 12 months

          7. Subjects who do not have suitable veins for multiple venepunctures/cannulation as
             assessed by the investigator at screening

          8. Clinically significant abnormal biochemistry, haematology or urinalysis as judged by
             the investigator

          9. Confirmed positive drugs of abuse test result

         10. Positive hepatitis B surface antigen (HBsAg), hepatitis C virus antibody (HCV Ab) or
             human immunodeficiency virus (HIV) results

         11. History of clinically significant cardiovascular, renal, hepatic, chronic respiratory,
             psychiatric or gastrointestinal (GI) disease as judged by the investigator

         12. Serious adverse reaction or serious hypersensitivity to any drug or the formulation
             excipients

         13. Presence or history of clinically significant allergy requiring treatment, as judged
             by the investigator. Hayfever is allowed unless it is active

         14. Donation or loss of greater than 400 mL of blood within the previous 3 months

         15. Subjects who are taking, or have taken, any prescribed or over-the-counter drug or
             herbal remedies in the 14 days before IMP administration. Exceptions may apply on a
             case by case basis, if considered not to interfere with the objectives of the study,
             as agreed by the PI and sponsor's medical monitor.

         16. Subjects who have taken any CYP3A4 inducers in the 30 days prior to IMP
             administration.

         17. Failure to satisfy the investigator of fitness to participate for any other reason
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Quotient Sciences Limited</name>
      <address>
        <city>Nottingham</city>
        <zip>NG11 6JS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>March 20, 2019</study_first_submitted>
  <study_first_submitted_qc>March 21, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 26, 2019</study_first_posted>
  <last_update_submitted>February 24, 2020</last_update_submitted>
  <last_update_submitted_qc>February 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 25, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aprepitant</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

